Ahmed Bennis
@drbennisahmed
Followers
532
Following
787
Media
1,489
Statuses
1,960
Professor of Cardiology FESC FHFA
Casablanca, Grand Casablanca
Joined August 2023
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#NevaPlay
• 529397 Tweets
SAROCHA X MODERN GURU
• 452359 Tweets
Tzuyu
• 370974 Tweets
Chiefs
• 366678 Tweets
namjoon
• 293632 Tweets
Ravens
• 260687 Tweets
Lamar
• 117474 Tweets
Adalet
• 91262 Tweets
Chester
• 70675 Tweets
#ZeeNunew1stFMinJapan
• 69931 Tweets
サブスク解禁
• 38644 Tweets
小泉進次郎
• 36415 Tweets
Hayırlı Cumalar
• 35239 Tweets
FANZA
• 32149 Tweets
小泉さん
• 22358 Tweets
MUSINSA BEAUTY WITH KARINA
• 20710 Tweets
TransisiSEJUK PRABOWOJKW
• 20082 Tweets
モモンガ
• 19339 Tweets
KitaKOMPAK KitaMENANG
• 19218 Tweets
ちいかわ寿司
• 17666 Tweets
アストロボット
• 17576 Tweets
資さんうどん
• 16085 Tweets
知的レベル
• 15875 Tweets
すかいらーく
• 15374 Tweets
KPLC
• 15187 Tweets
進次郎さん
• 12639 Tweets
資さん買収
• 12605 Tweets
Engin Polat
• 12372 Tweets
ベイマックス
• 11864 Tweets
PRETTY GIRL ERA MILKLOVE
• 11594 Tweets
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2
Continuation of sacubitril/valsartan was associated with persistent clinical benefit and no incremental safety risk
2
12
39
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Patients with deterioration of eGFR to <25 mL/min/1.73 m2 had elevated risks of CV outcomes yet appeared benefit from continuation of dapagliflozin with no excess in safety
0
10
34
Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF
high prevalence of unrecognized HFpEF in patients with dyspnea and AF when evaluated by definitive testing
0
12
34
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
Bempedoic acid in statin-intolerant
treat-to-target or high-intensity statin
Role of age on statin response
Semaglutide in obese
Tirzepatide
DAPAGLIFOZIN
0
10
33
Global epidemiology of heart failure
proud to be one of the authors of this article published in Nature Reviews Cardiology
HF is a major global health concern, with an increasing prevalence driven by ageing populations
2
12
32
I am proud to be part of the team that manuscript ‘’ Global Epidemiology of Heart Failure ‘’ has been accepted for publication in Nature Reviews Cardiology with Pr Javed Butler , Dr Muhammad Khan, Dr Izza Shahid, Pr Amina Rakisheva and Pr Marco Metra .
4
4
30
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial
The FINEARTS-HF trial will determine the efficacy and safety of the non-steroidal MRA finerenone in HFPEF
0
10
29
Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation
Diltiazem reduced NT-proBNP levels and improved rhythm-related symptoms.
1
9
27
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF
Dapagliflozin reduced the risk of the primary outcome, regardless of QRS duration, in DAPA-HF and DELIVER
0
10
28
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2
Continuation of sacubitril/valsartan in patients with below eGFR 30 mL/min/1.73 m2 was associated with clinical benefit and no incremental safety risk
0
9
27
What's new in heart failure? June–July 2024
A smartphone-based approach to HF diagnosis
Efficacy and safety of mineralocorticoid receptor antagonists in patients with worsening renal function
Timing to recovery of left ventricular function in de novoHF
0
9
26
Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review
Tachycardia, AF, and PVCs can result in cardiomyopathy or AiCM
Appropriate treatment of AiCM can reverse ventricular systolic dysfunction and potentially decrease morbidity and mortality.
0
9
26
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis
Treatment with SGLT-2 inhibitors led to a significant reduction in HF events in patients with CKD
0
6
25
Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
For patients with heart failure, MRA was of high value, SGLT2i was of intermediate value, and ARNI was of low value in both HFmrEF and HFpEF
0
8
24
FLOW Trial a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Sema 1.0mg once weekly in CKD+T2D
✅ ↓ Composite kidney events
✅ Slower eGFR decline
✅ ↓ MACE
✅ ↓ All-cause mortality
1
9
23
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
semaglutide improved HF-related symptoms and physical limitations across diuretic use subgroups
0
7
24
Guideline-recommended medical therapy for de novo heart failure with reduced ejection fraction: be patient waiting for reverse remodelling
early initiation and optimization of GRMT lead to recovery of LV function well beyond the conventional 90-day mark
0
10
24
Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart FailureGuideline Comparison
Globally, HF remains a leading cause of death, disability, and health care expenditures, practice patterns may differ internationally
0
9
24
Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study
GDMT for at least 180 days in HFrEF associated with additional LVEF improvement > 35%
0
8
23
Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
MRA was of high value, SGLT2i was of intermediate value, and ARNI was of low value in both HFmrEF and HFpEF
0
9
23
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF
Empagliflozin inhibits Na influx and late INa, which could contribute to anti-arrhythmic effects in patients with HFpEF
1
6
23
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization.
Dapagliflozin associated with enhanced diuresis among patients with AHF
0
9
23
European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The Heart Failure Association of the ESC
ESC QIs for heart failure to ensure that these measures are aligned with contemporary evidence
0
9
22
Role of anti-obesity drugs in heart failure
regardless of ejection fraction
1
10
23
Use of new and emerging cancer drugs: what the cardiologist needs to know
Cardio-oncology is a subspecialty of medicine focusing on the identification and prevention of cancer therapy–related cardiovascular toxicity (CTR-CVT)
0
4
20
Evaluation and Management of Hyponatremia in Heart Failure
For decongestive treatment, proximally acting diuretics such as sodium-glucose co-transporter-2 inhibitors, acetazolamide, and loop diuretics are the preferred options.
0
9
20
Low-dose colchicine for atherosclerosis: long-term safety
Low-dose colchicine (0.5 mg daily) is now FDA-approved for secondary prevention in patients with coronary disease
2
7
21
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF
Empagliflozin inhibits Na influx and late INa, which could contribute to anti-arrhythmic effects in patients with HFpEF
1
5
20
Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction
The DEFENDER Randomized Clinical Trial
The addition dapagliflozin to standard care for individuals critical illness and acute organ dysfunction did not improve clinical outcomes
0
3
20
European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The HFA of the ESC
update of the previously published ESC QIs for HD to ensure that these measures aligned with contemporary evidence
0
9
20
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial
not see significant reduction UACR in balcinrenone plus dapagliflozin compared with dapagliflozin
@mvaduganathan
0
3
20
Prognostic impact of beta-blocker use by N-terminal pro-brain natriuretic peptide level in acute heart failure patients
In patients with acute HF, BB use is associated with reduced all-cause mortality in those with HFrEF but not in those with HFpEF
0
12
21
Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
elevated levels of TG , and very-low-density lipoproteins (VLDL), are an independent risk factor for ASCVD
0
9
19
Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management
under-representation this patient group in RCTs invasive management in NSTE-ACS
0
6
18
#HeartFailure2024
Design and baseline characteristics of FINE-HEART: an integrated pooled analysis of finerenone in >19,000 participants across 3 phase III trials of HF & CKD
0
3
19
Ticagrelor 60 vs. 90 mg in Elderly ACS Patients undergoing PCI: Randomized, Crossover Trial
ticagrelor 60 mg twice daily provided similar magnitude of platelet inhibition compared with ticagrelor 90 mg twice daily among elderly patients undergoing PCI
0
2
19
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
absolute RR with an MRA in eGFR to <30 mL/min/1.73 m2 is large and this decline in eGFR should not automatically lead to treatment discontinuation
0
8
20
Renal Compression in Heart Failure: The Renal Tamponade Hypothesis
The rigidness of the renal capsule is central in congestion-induced damage to the renal structures
Renal decapsulation has been shown to be beneficial in animals
@SJGreene_md
0
5
18
Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation
no differences regarding the risk of stroke/TE, but apixaban was associated with a 21% lower relative risk of major bleeding compared to VKA
0
5
19
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway
Intravenous iron therapy with FCM delivers iron to myocardium rapidly through NTBI transporters independently reticuloendothelial macrophage
0
10
19
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
inclisiran demonstrated sustained and substantial LDL-C lowering with a favourable long-term safety and tolerability profile
2
4
18
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
benefits semaglutide in reducing kidney outcomes were consistent in with/without baseline SGLT2i use
0
1
17
Identification of three mechanistic pathways for iron-deficient heart failure
all pathways may be operative at the same time or may occur sequentially in the same patients
0
2
18
#HeartFailure2024
Cardiac reverse remodeling in the trial of accelerated guideline-directed medical therapy for Heart Failure (TEAM-HF)
Amazing
0
3
17
#ERA24
FLOW trial
Amazing
20% lower risk of overall death
18% lower risk of CV death, non-fatal Mi or non-fatal stroke
@JJheart_doc
1
2
18
Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction
still not evidence-based whether SGLT2 inhibition should precede other GRMT drugs in patients with de novo HF
0
8
18
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure , and response to sacubitril/valsartan in PARAGON-HF
Treatment effects of sacubitril/valsartan were consistent irrespective of CKM burden
0
12
19
#HeartFailure2024
First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure
2
3
18
Use of Sodium–Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
Initiating SGLT2 inhibitors early during a hospital stay offers a strategic approach to optimize patient care and overcome barriers to initiation
0
3
16
The ‘10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
•Screening and cardiovascular risk assessment
• Person -centred treatment strategies in patients with type 2 diabetes
0
6
17
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS
The overall risk of death due to stroke or bleeding was low in XANTUS
0
7
18
Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies—a review
Shortening ischaemic times by fine-tuning collaboration networks between ambulances, community hospitals, and tertiary care
0
7
16
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure:
A pre-specified analysis from the from the SELECT trial
The demonstrated benefits of semaglutide were not different in HFpEF compared to HFrEE
@mvaduganathan
0
5
16
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry
Frailty in patients at risk for advanced HF, assessed via a multi-domain approach and the FI, is highly prevalent
0
7
16
Long-term Effects of Phosphodiesterase-5 Inhibitors on Cardiovascular Outcomes and Death: A Systematic Review and Meta-analysis
PDE5i primarily in men with or without known CAD associated with a lower risk for CV events and overall mortality
0
5
16
Hypoalbuminaemia and heart failure: A practical review of current evidence
albumin supplementation or nutritional support would be beneficial in improving clinical outcomes in HF is not clear and should be evaluated in adequately designed studies
0
6
16
Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque
Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA
0
3
16
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
neprilysin inhibition and SGLT2 inhibition have shown beneficial effects on reducing the risk of developing heart failure but with no effect on mortality
0
3
15
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort
higher Lp(a) levels are associated with an increased ASCVD risk, including in patients with diabetes.
1
3
16
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
A Systematic Review and Patient-Level Meta-Analysis
ticagrelor monotherapy was similarly effective and safer than DAPT
0
2
16
Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study
use and dose of GDMT were suboptimal, with the reasons often remaining unclear
0
12
15
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program
Semaglutide consistently improved HF-related symptoms, physical limitations, and exercise function, and reduced bodyweight
0
3
16
#HeartFailure2024
Do we need artificial intelligence for heart failure?
"Doctors and nurses who use Al will replace doctors and nurses who don't"
0
4
16
Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin
The gout and cardiovascular benefits associated with SGLT2
0
1
16
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
decrease in eGFR to <30 mL/min/1.73 m2 are at very high risk
decline in eGFR should not automatically lead to treatment discontinuation.
0
13
16
Left Main Coronary Artery Calcium and Diabetes Confer Very-High-Risk Equivalence in Coronary Artery Calcium >1,000
asymptomatic patients with a CAC of ≥1,000 without a prior index event, diabetes, and severe LM CAC define very high risk ASCVD
0
7
15
Indexing left ventricular end-systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation
In severe DMR due to flail leaflets, LVESDi is a marker of risk additive and incremental to LVESD
0
5
14
Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry
females and males might differently benefit from the same dose of RASI/ARNI
0
6
15
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors
The biomarker-based diagnostic model proves effective in ruling out LV dysfunction
potential to minimize unnecessary echocardiography in childhood cancer survivors
0
5
15
Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy
novel drug therapy targeting myocardial energetics was safe and well tolerated and associated with better exercise performance
0
7
15
Design and Rationale of the Engage-HF Study: The Impact of a Gamified Engagement Toolkit on Participation and Engagement in a Heart Failure Registry
The ENGAGE-HF study is the first to explore the impact of education
0
4
14
Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials
In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding
0
7
15
#HeartFailure2024
Management of acute and residual congestion in patients with acute heart failure by adding dapaglifozin (SGLT2) to intravenous loop diuretic therapy - ENDORSE - HF
0
2
15
Oral anticoagulation in patients with left ventricular thrombus – a systematic review and meta-analysis
DOACs was not associated with a significant difference in stroke or systemic embolism, or thrombus resolution compared to VKA therapy
0
3
14
Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the HF Association of the ESC
whole scenario of available evidence on sex-disparities in HF and aims to define urgent residual gaps
@gcfmd
0
6
15
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
neprilysin inhibition and SGLT2 inhibition have shown beneficial effects on reducing the risk of developing heart failure but with no effect on mortality
0
6
15
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI
Following acute MI, patients assigned to sacubitril/valsartan had a higher frequency of initial increases in serum creatinine at 1 week
0
6
15
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion
@mvaduganathan
0
2
15
Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 h
2-h algorithm using a POC hs-cTnI concentration enables safe and efficient risk assessment of patients with suspected AMI
0
2
13
Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review
Tachycardia, AF, and PVCs can result in cardiomyopathy or AiCM.
Appropriate treatment of AiCM can reverse ventricular systolic dysfunction and potentially decrease morbidity
0
3
14
Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review
Early trials of intravenous iron repletion in patients with heart failure found improvements in symptoms and functional capacity
0
4
14
#HeartFailure2024
10 messages to remember from HFA 2024
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure:
Message 5: Semaglutide reduced the risk of MACE and HF composite in HFrEF and HFpEF
0
3
14
Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score
Adding cancer to the PRECISE-DAPT score identifies the majority of patients with cancer as HBR
0
7
14
What's new in heart failure? June–July 2024
Efficacy and safety of mineralocorticoid receptor antagonists in patients with worsening renal function
careful monitoring and management are essential to ensure continued therapeutic benefit
0
4
14
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
decrease in eGFR to <30 mL/min/1.73 m2 are at very high risk, the absolute risk reduction with an MRA in these patients is large
2
4
13
Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis
Drugs targeting the three traditional treatment pathways significantly improve outcomes in PAH, with significant treatment heterogeneity
0
4
14
Hypertension and Kidney Function After Living Kidney Donation
living donors had a similar risk of hypertension as nondonors in the 7 years following donation and no significant difference in mean blood pressure
0
5
14
Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations
Enrollment diversity in clinical trials may affect who receives early application of recently approved innovations.
0
4
14
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering
0
6
14
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
neprilysin inhibition and SGLT2 inhibition have shown beneficial effects on reducing the risk of developing heart failure but with no effect on mortality
1
4
14
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
Novel druggable therapeutic targets and compounds for antiplatelet therapy are currently in pre-clinical development, and some appear to have a more favourable safety profile
0
2
14
Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: A multicenter propensity score matched study
SGLT2i can be used to reduce the burden of cardiovascular disease in KTRs with diabetes
0
5
14
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes
0
1
13
Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
one-quarter of patients with HF with mildly reduced/preserved ejection fraction had a low NT-proBNP level and favorable prognosis
0
4
14
Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis
quadruple combination of ARNI, BB, MRA, and SGLT2i provides the largest reduction in the risk of CV death and HHF
0
3
14
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases
0
4
14
Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature
Infancy-onset 20-year dietary intervention had favourable effects on the retinal microvasculature in young adulthood
0
0
14
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial
first-line SGLT2i in T2D and HF
0
6
13
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Management of diabetic kidney disease (DKD) has evolved in parallel with our growing understanding of the multiple interrelated pathophysiological mechanisms hemodynamic, metabolic
1
8
13
Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
Novel strategies targeting multiple pathways offer hope for effectively improving cardiometabolic health
1
4
14